SAN DIEGO, California — May 6, 2026 — Leads & Copy — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the Bank of America Securities 2026 Healthcare Conference. A fireside chat featuring Kura management is scheduled for May 13, 2026, at 6:00 p.m. ET / 3:00 p.m. PT.
The live webcast and archived replay will be available in the Investors section of the company’s website.
Kura Oncology is dedicated to developing precision medicines for cancer, focusing on small molecule drug candidates targeting cancer signaling pathways to treat hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition.
Source: Kura Oncology
